

1 **Title: Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for**
2 **COVID-19 Adjuvanted with AS03**

3
4 **Authors:** Karen Joyce Hager¹, Gonzalo Pérez Marc², Philippe Gobeil¹, Ricardo Sobhie
5 Diaz³, Gretchen Heizer¹, Conrado Llapur⁴, Alexander I. Makarkov¹, Eduardo
6 Vasconcellos⁵, Stephane Pillet¹, Fernando Riera⁶, Kapil Bhutada¹, Priscila Geller
7 Wolff⁷, Garry Wallace⁸, Hessam Aazami⁹, Christine E. Jones¹⁰, Fernando P. Polack¹¹,
8 Judith Atkins¹, Iohann Boulay¹, Jiwanjeet Dhaliwall¹, Nathalie Charland¹, Manon
9 Couture¹, Julia Jiang-Wright¹, Nathalie Landry¹, Sophie Lapointe¹, Aurélien Lorin¹,
10 Asif Mahmood¹, Lawrence H. Moulton¹², Emmy Pahmer¹, Julie Parent¹, Pooja Saxena¹,
11 Annie Séguin¹, Luan Tran¹, Thomas Breuer¹³, Maria Angeles Ceregido¹³, Marguerite
12 Koutsoukos¹³, François Roman¹³, Junya Namba¹, Marc-André D'Aoust¹, Sonia
13 Trepanier¹, Yosuke Kimura¹, The CoVLP Study Team, Brian J. Ward^{1,14*}.

14
15 ¹ Medicago Inc., 1020 route de l'Église, Bureau 600, Québec, QC, Canada, G1V 3V9

16 ² Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Av. Luis Maria
17 Campos 726, Buenos Aires Buenos Aires C1426, Argentina

18 ³ Infectious Diseases Division, Paulista School of Medicine, Federal University of Sao
19 Paulo, Brazil, and Azidus Brasil Pesquisa e Desenvolvimento Ltda, Valinhos São Paulo
20 13271-130, Brazil

21 ⁴ Clinica Mayo de UMCB SRL, Combate de San Lorenzo 449, San Miguel de Tucumán
22 Tucumán T4000, Argentina

23 ⁵ Instituto de Pesquisas Clinicas L2IP, SGAS 613 - lote 95 - Bloco A, Sala 6, Ed. L2

24 Complexo Médico Hospitalar, DF 70200-730, Brazil

25 ⁶ Sanatorio Allende, Av. Hipolito Yrigoyen 384, Cordoba, Cordoba 5000, Argentina

26 ⁷ IBPClin Instituto Brasil de Pesquisa Clinica, R. Da Gloria, 344 – Gloria, Rio de Janeiro

27 RJ 20241-180, Brazil

28 ⁸ Dawson Clinical Research Inc., 83 Dawson Road, Guelph, Ontario N1H 1B1, Canada

29 ⁹ Hope Clinical, 22030 Sherman Way, Canoga Park, California 91303, United States

30 ¹⁰ Clinical and Experimental Sciences, University of Southampton and NIHR

31 Southampton Clinical Research Facility and Biomedical Research Centre, University

32 Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16

33 6YD, United Kingdom

34 ¹¹ Fundacion INFANT, Gavilán 15, Buenos Aires, Argentina

35 ¹² Department of International Health, Johns Hopkins Bloomberg School of Public

36 Health, 615 N. Wolfe St., Baltimore, MD 21217, USA.

37 ¹³ GlaxoSmithKline Vaccines, Wavre, Belgium

38 ¹⁴ Research Institute of the McGill University Health Center, 1001 Decarie St,

39 Montréal, QC, Canada H4A 3J1

40

41 * Corresponding author:

42 Brian J. Ward

43 1020 Route de l'Église, Bureau 600

44 Québec, QC, Canada

45 G1V 3V9

46 Tel. 418 658 9393

47 Fax. 418 658 6699

48 wardb@medicago.com

49

50 **Keywords**

51 Phase 3, SARS-CoV-2, COVID-19 Vaccine, Virus-Like Particles, *Nicotiana*

52 *benthamiana*, Safety, Efficacy, Variants, Delta, Gamma, Cross-Protection

53 **Abstract**

54 **Background:** Several COVID-19 vaccines are currently being deployed but supply constraints,
55 concerns over durability of immune responses, solidifying vaccine hesitancy/resistance and
56 vaccine efficacy in the face of emerging variants mean that new vaccines continue to be needed
57 to fight the ongoing pandemic. The vaccine described here is an enveloped, coronavirus-like
58 particle produced in plants (CoVLP) that displays the prefusion-stabilized spike (S)
59 glycoprotein of SARS-CoV-2 (ancestral Wuhan strain) and is adjuvanted with AS03
60 (CoVLP+AS03).

61 **Methods:** This Phase 3 randomized, observer-blind, placebo-controlled trial was conducted at
62 85 centers in Argentina, Brazil, Canada, Mexico, the UK, and the USA. Adults ≥ 18 years of
63 age including those at high risk for COVID-19 complications were randomly assigned 1:1 to
64 receive two intramuscular injections of CoVLP (3.75 μ g) adjuvanted with AS03 or placebo, 21
65 days apart. The primary efficacy endpoint was prevention of symptomatic (≥ 1 symptom),
66 PCR-confirmed SARS-CoV-2 infection with onset at least 7 days after the second injection and
67 was triggered by the identification of ≥ 160 virologically-confirmed cases. Tolerability and
68 safety of CoVLP+AS03 were also determined.

69 **Results:** A total of 24,141 volunteers were randomly assigned 1:1 to receive vaccine or placebo
70 (N= 12,074 and 12,067, respectively: median age 29, range 18 to 86 years). Overall, 83%
71 received both doses. 14.8% were SARS-CoV-2 seropositive at baseline. Symptomatic SARS-
72 CoV-2 infection was confirmed in 165 study participants in the intention to treat (ITT) set and
73 157 in the per-protocol population (PP) set. Of the 157 in the PP set, 118 COVID-19 cases were
74 in the placebo group and 39 COVID-19 cases were in the CoVLP+AS03 group for an overall
75 vaccine efficacy (VE) of 71.0% (95% confidence interval (CI) 58.6, 80.0). Moderate-to-severe
76 COVID-19 occurred in 8 and 32 participants in the CoVLP+AS03 and placebo groups,
77 respectively: VE 78.1% (95% CI: 53.9, 90.5) in the PP set overall and 84.5% (95% CI: 62.0,
78 94.7) in those seronegative at recruitment.

79 To date, 100% of the sequenced strains (122/165 cases: 73.39%) were variants, dominated by
80 Delta (45.9%) and Gamma (43.4%) strains. Vaccine efficacy by variant was 75.3% (95% CI
81 52.8, 87.9) against Delta and 88.6% (95% CI 74.6, 95.6) against Gamma. Cross-protection was
82 also observed against Alpha, Lambda and Mu variants; although fewer cases were identified,
83 all were in the placebo group. At diagnosis, viral loads in the CoVLP+AS03 breakthrough
84 cases were >100 -fold lower than in the placebo cases. Reactogenicity data for solicited adverse

85 events (AEs) was analysed for a subset (N=4,136 in vaccine arm and N=3,683 for placebo) of
86 participants. Reactogenicity was mostly mild to moderate, and transient, and occurred more
87 frequently in the CoVLP+AS03 group. The safety analysis set used for unsolicited AE
88 assessment comprised 24,076 participants who received at least one study injection: 12,036
89 received CoVLP+AS03 and 12,040 received placebo. All serious adverse events were assessed
90 as unrelated, except two events reported in the same subject in the placebo group. No
91 significant imbalance or safety concern was noted in medically attended AEs (MAAEs),
92 adverse event of special interest (AESIs), AEs leading to withdrawal, deaths, or adverse events
93 potentially associated with currently authorized vaccines.

94 **Conclusions:** The CoVLP+AS03 vaccine candidate conferred an efficacy of 71.0% in
95 preventing symptomatic SARS-CoV-2 infection caused by a spectrum of variants. Vaccine
96 efficacy of 78.1% was observed against moderate and severe disease, while variant-specific
97 efficacy ranged from 75.3% to 100%. Markedly lower viral loads in the CoVLP+AS03 group at
98 the time of diagnosis suggests a significant virologic impact of vaccination even in the
99 breakthrough cases. CoVLP+AS03 vaccine candidate was well tolerated, and no safety
100 concerns were identified during the study. If approved by regulators, this more traditional
101 protein+adjuvant vaccine produced using the novel plant-based platform may be able to make
102 an important contribution to the global struggle against the increasingly complex family of
103 SARS-CoV-2 viruses (Funded by Medicago with grants from the governments of Quebec and
104 Canada; NCT04636697).

105 **Introduction**

106 Since its emergence in late 2019 ¹, the severe acute respiratory syndrome coronavirus 2 (SARS-
107 CoV-2) has caused more than 312 million cases of coronavirus disease 2019 (COVID-19)
108 globally with >5.5 million deaths ². A massive global effort began almost immediately upon
109 recognition of the new virus that resulted in the development of a large diversity of vaccine
110 candidates based on mRNA, non-replicating adenovirus-vectored, attenuated and inactivated
111 viruses, and adjuvanted protein-based platforms ³. The spike (S) glycoprotein contains a
112 receptor binding domain (RBD) that binds to human angiotensin-converting enzyme 2 (ACE2)
113 receptor which initiates viral fusion and entry into host cells ^{4,5}. Neutralizing antibodies (NAb)
114 directed against the S protein provide protection from other highly pathogenic coronaviruses
115 (e.g.: SARS-CoV-1, MERS) and similar protective efficacy was rapidly demonstrated with
116 anti-S antibodies in SARS-CoV-2 infection ⁶. Consequently, the S protein is the target for
117 almost all COVID-19 vaccines except for attenuated and inactivated virus-based vaccine
118 candidates. Phase 3 clinical trials launched during the first waves of the pandemic generally
119 demonstrated high vaccine efficacy against the ancestral (Wuhan) SARS-CoV-2 strain ⁷.
120 Several vaccines have since been deployed around the world with considerable success ⁸⁻¹⁰ and
121 acceptable safety profiles despite some concerns regarding rare cases of myocarditis and
122 pericarditis after mRNA vaccines ¹¹ and thrombotic events associated with some adenovirus
123 vectored vaccines ¹² which have been added to the prescribing information. However, the
124 reduced protection reported more recently, from clinical trials and subsequent real-world data
125 ¹³⁻¹⁷, may be due to a combination of reduced cross-reactivity of vaccine-induced antibodies
126 against emerging SARS-CoV-2 variants and waning vaccine-induced humoral immunity with
127 time, especially for mild disease ^{18,19}. A third dose (booster) of the mRNA vaccines has been
128 reported to restore serum NAb levels and improve cross-protection against emerging variants,
129 especially against the most severe outcomes ²⁰. Tensions created by the simultaneous demand
130 for booster doses in countries with largely immunized populations and the need to provide
131 primary vaccination to the majority of the world's unvaccinated populations ^{6,21,22} emphasize
132 the need for additional vaccines and vaccine suppliers to fully meet the global demand.
133 Alternative vaccine options that can be used under routine storage and handling conditions (2-
134 8°C) or that can overcome the concerns of individuals who hesitate to get vaccinated with
135 currently licensed vaccines based on novel platform technologies due to medical conditions or
136 beliefs ²³ would also be useful.

137 Virus-like particles (VLP)-based vaccine have been highly successful against several viral
138 pathogens such as the Hepatitis B virus and the Human Papillomavirus ²⁴. Medicago has
139 developed a plant-based production platform to generate VLPs for a range of viral pathogens
140 including enveloped VLP candidates for pandemic and seasonal influenza that have
141 demonstrated substantial immunogenicity or efficacy in human studies ²⁵⁻²⁹. This vaccine
142 manufacturing platform uses transient transfection of *Nicotiana benthamiana*, a common
143 Australian plant and a disarmed *Agrobacterium tumefaciens* vector to deliver the episomal
144 DNA encoding the vaccine protein to the plant cell nucleus ³⁰. Expression of the full-length,
145 pre-fusion-stabilized SARS-CoV-2 S protein (ancestral Wuhan strain) in plant cells results in
146 the spontaneous formation of 100-150 nm enveloped VLPs (hereafter referred to as CoVLP).
147 Once purified, CoVLP is stable for at least 6 months under routine vaccine
148 storage/transportation conditions (2-8°C). The Adjuvant System 03 (AS03) is an established
149 adjuvant manufactured by GlaxoSmithKline (GSK). AS03 initiates a transient innate response
150 at the injection site and the draining lymph node in animal models ³¹, and in human peripheral
151 blood cells³²⁻³⁴. This innate immune activity potentiates and shapes both the humoral and cell-
152 mediated adaptive responses to the vaccine antigen, resulting in increased magnitude, quality
153 (e.g.: antibody avidity), breadth and durability of the immune responses ³⁵⁻³⁹. AS03 has been
154 used to adjuvant pandemic A/H1N1pdm09 influenza vaccines (>90 million doses pandemic
155 influenza vaccines have been administered worldwide), as well as in other licensed vaccines or
156 vaccine candidates ⁴⁰. AS03-adjuvanted CoVLP (CoVLP+AS03) has been shown to induce
157 strong and durable neutralizing antibody responses, as well as a balanced IFN- γ /IL-4 T cell
158 response ^{41,42}, both of which are likely to be important in protecting against SARS-CoV-2
159 infection ⁴³.

160 We report herein the results of the pivotal Phase 3 portion of a Phase 2/3 study in which the
161 safety and efficacy of CoVLP+AS03 were evaluated in 24,141 adult participants ≥ 18 years of
162 age recruited between March 15th, 2021, and September 2nd, 2021, in six countries across three
163 continents (Europe, North and South America). This placebo-controlled trial was conducted
164 during an evolving pandemic environment with active circulation of several variants of concern
165 and of interest, as well as increasing vaccine roll-out.

166

167

168 **Methods**

169 *Trial Objectives and Oversight*

170 The trial is being conducted in accordance with current International Conference on
171 Harmonization (ICH) guidelines on Good Clinical Practice, and applicable country-specific
172 regulatory requirements. All participants provided written informed consent before being
173 enrolled. An independent Institutional Review Board (IRB) or Ethics Committee (EC)
174 approved the protocol, protocol amendments and consent forms. Safety and efficacy data, as
175 required by protocol, was reviewed by an Independent Data Monitoring Committee (IDMC) as
176 needed.

177 The objectives of the randomized, observed-blinded, placebo-controlled Phase 3 portion of the
178 trial were the determination of efficacy, safety and, in a subset of participants, immunogenicity
179 of CoVLP+AS03. The trial involved 85 sites in Argentina, Brazil, Canada, Mexico, the United
180 Kingdom, and the United States of America. Once at least 160 laboratory-confirmed COVID-
181 19 cases (≥ 7 days post second vaccination) were collected, and a median safety follow-up of at
182 least 2 months (post second dose) was achieved in at least 3,000 participants in each of the
183 CoVLP+AS03 and placebo groups, the database was cleaned, a snapshot was taken, and the
184 primary efficacy results were calculated. The cut-off dates for inclusion in the vaccine efficacy
185 analyses and safety analyses were August 20th, 2021 and October 25th, 2021, respectively.

186 Medicago Inc. was responsible for the overall trial design and oversight, as well as the
187 manufacture of CoVLP. GSK was responsible for the manufacture of AS03 and providing input
188 into trial design. Site selection and monitoring and conduct of the trial was delegated by
189 Medicago to Syneos (Canada). Data were collected by site investigators (complete list of
190 investigators provided in supplementary materials). Data were centralized and analyzed in
191 conjunction with Syneos. PCR testing and genetic analysis of viral samples was performed by
192 Viroclinics-DDL (Netherlands).

193 Safety oversight was provided by the Safety Monitoring Team (SMT) that reviewed safety data
194 on a regular basis in a blinded manner. This included data on AESIs including potential
195 Immune Mediated Disorders (pIMDs), Anaphylaxis and severe allergic reactions, Vaccine-
196 associated enhanced diseases (VAED), or Vaccine-associated enhanced respiratory diseases
197 (VAERD), with triggers in place to escalate to the IDMC if a potential safety signal was
198 identified. In parallel an unblinded medical monitor was reviewing unblinded data on a real
199 time basis to escalate to the IDMC if a stopping rule was met. The safety and efficacy data were

200 also reviewed by the IDMC, to confirm that the primary efficacy endpoint had been met, and
201 that the benefit/risk profile was positive.

202 The trial is ongoing and, at the time of writing, the investigators remained unaware of
203 participant-level treatment assignments. Limited team members have unblinded access to the
204 data to facilitate submission of clinical safety findings to regulatory agencies and the IDMC.
205 All other trial staff and participants remain unaware of treatment assignments.

206

207 *Participants and Randomization*

208 Study participants were adults aged 18 years or older and included younger adults aged 18-64
209 (Population 1), older adults aged 65 or more (Population 2) and adults aged 18 or more with
210 significant comorbidities (Population 3). High-risk comorbidities in Population 3 included, but
211 were not limited to obesity, hypertension, diabetes (type 1 or 2), chronic obstructive pulmonary
212 disease, cardiovascular disease, asthma and immunocompromise due to treatment-controlled
213 HIV, organ transplant, or receipt of cancer chemotherapy (full details in Supplementary Table
214 S2). Participants had not previously received any SARS-CoV-2 vaccine and must not have had
215 a history of virologically confirmed COVID-19. Full inclusion and exclusion criteria are
216 detailed in the trial protocol (available in supplementary materials).

217 Participants were assigned in a 1:1 ratio to receive either CoVLP+AS03 or placebo. The
218 vaccine candidate or placebo (0.5 mL) were injected intramuscularly, 21 days apart, in
219 contralateral (when possible) deltoid muscles by an unblinded site staff member. Participants
220 were observed by blinded site staff responsible for safety evaluations for 30 minutes after each
221 vaccination.

222

223 *Trial Vaccine*

224 The CoVLP vaccine candidate, previously described in detail ⁴², is composed of full-length
225 spike (S) protein in a pre-fusion stabilized configuration from SARS-CoV-2 (strain hCoV-
226 19/USA/CA2/2020) incorporating the modifications: R667G, R668S, R670S, K971P, and
227 V972P expressed in the leaves of *Nicotiana benthamiana* by *Agrobacterium*-based transient
228 transfection. High-level expression of the S protein results in formation of S trimers at the
229 plasma membrane followed by spontaneous budding of CoVLPs. AS03 adjuvant is an oil-in-
230 water emulsion containing DL- α -tocopherol and squalene, supplied by GSK. Immediately prior

231 to use, 2.5 mL of CoVLP and 2.5 mL of AS03 are mixed in a multidose vial to obtain 10
232 vaccine doses of 0.5 mL each. Each dose of the vaccine contained 3.75 µg of CoVLP
233 formulated in phosphate-buffered saline (PBS) with polysorbate 80, 11.86 mg of DL-α-
234 tocopherol and 10.69 mg of squalene. The placebo was composed of 0.5 mL PBS with
235 polysorbate 80.

236

237 *Safety Assessments*

238 The safety analysis included all data collected as of October 25th, 2021. The safety analysis set
239 (SAS) used to evaluate unsolicited data including AESIs and SAEs comprised 24,076
240 participants: 12,036 in the CoVLP+AS03 arm, and 12,040 in the placebo arm. Reactogenicity
241 data for solicited AEs were analysed for a subset (N=4,136 in vaccine arm and N=3,683 for
242 placebo) of participants who had received both doses following the protocol-prescribed dosing
243 regimen and who had completed at least 2 months of safety follow-up, post dose 2.

244 Solicited local or systemic adverse events within 7 days of receiving each dose were collected
245 using paper or electronic diaries. Unsolicited AEs were monitored for 21 days after each dose,
246 while SAEs, MAAEs, AEs leading to withdrawal, AESIs (including VAED/VAERD,
247 anaphylaxis and severe allergic reactions, pIMDs), and deaths are being monitored throughout
248 the study. AE grading criteria as well as pre-defined study specific stopping rules for safety
249 reasons are detailed in the clinical study protocol (available in supplementary materials).

250

251 *Efficacy Assessments*

252 The primary efficacy endpoint was the prevention of symptomatic SARS-CoV-2 infection
253 seven or more days after receipt of the second dose (Primary Vaccine Efficacy; PVE). COVID-
254 19 cases were adjudicated by a subcommittee of the IDMC, blind to group assignment, and
255 were defined by the presence of at least one of the following symptoms: fever or chills, cough,
256 shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, loss of
257 taste or smell, sore throat, congestion or runny nose, nausea or vomiting, diarrhea, and a
258 positive SARS-CoV-2 test (on nasopharyngeal (NP) or nasal swabs) by quantitative reverse-
259 transcriptase polymerase chain reaction (qRT-PCR) performed by a central virological
260 laboratory (ViroClinics-DDL: Rotterdam, Netherlands) that provided both qualitative (i.e.:
261 positive-negative) and quantitative results (i.e.: viral load: copies/mL; cp/ml).

262 Efficacy assessments that can be reported at this time are vaccine efficacy in preventing
263 laboratory-confirmed moderate and severe COVID-19, viral load at the time of diagnosis, and
264 efficacy of the vaccine in preventing laboratory-confirmed COVID-19 by variants seven days
265 or more after the second dose. COVID-19 severity assessment was based on FDA guidance
266 criteria and severe COVID-19 was further defined in the protocol.

267 Viral load was determined by Viroclinics using RT-qPCR targeting the nucleocapsid gene.
268 Primers and assay conditions were based on CDC N1 assay ⁴⁴. The resulting cycle threshold
269 (Ct) values were plotted against a four-point standard curve with a known number of log₁₀
270 cp/mL run together with the real-time PCR. Ct values were converted to log₁₀ cp/mL based on
271 the slope and intercept of the standard curve for each analysis.

272

273 *Viral Sequencing*

274 Sequencing of viral genomes from swabs was performed by Viroclinics-DDL. Total nucleic
275 acid was extracted from samples using MagMAX™ Total Nucleic Acid Isolation Kits
276 (ThermoFisher) and full-length amplification of the target RNA, i.e., RNA encoding S, was
277 performed by nested RT-PCR. Next-generation sequencing platforms (MiSeq and NextSeq
278 Illumina) were deployed to analyze the sequences of the amplicons and the SARS-CoV-2
279 Wuhan-Hu-1 (GenBank: MN908947.3) was used as the reference sequence for amplicon
280 mapping. A detailed protocol is included in the supplementary material section.

281

282 *Statistical Analysis*

283 The full statistical analysis plan is included as a supplementary material.

284 Safety analyses were descriptive in nature and summarized as counts and percentages. No
285 statistical tests were performed. Safety analyses presented herein include solicited and
286 unsolicited adverse events occurring on or after vaccination and coded as per Medical
287 Dictionary for Regulatory Activities (MedDRA) v24.0.

288 Efficacy analyses of the primary endpoint included all laboratory confirmed cases that met the
289 definition of a COVID-19 case as adjudicated by the IDMC subcommittee. In order for a
290 COVID-19 case to be considered as a primary endpoint, symptoms had to start 7 or more days
291 after second dose and before the subject was unblinded to study treatment or was administered
292 a currently deployed COVID-19 vaccine. Symptom start was required to occur on or before

293 August 20th, 2021, to be included in the analysis of the primary endpoint. The IDMC
294 subcommittee provided confirmation that a COVID-19 case met the requirements for the
295 primary endpoint and assessed severity according to FDA criteria ⁴⁵.

296 Vaccine efficacy was calculated as $100 \times (1 - \text{incidence rate ratio})$ where the incidence rate
297 ratio is defined as the ratio of person-years rate of COVID-19 cases in the CoVLP+AS03 group
298 relative to the COVID-19 cases in the placebo group. For both analysis sets, censoring was
299 performed at the earlier of any of the following events, namely, when the subject experienced
300 their first virologically confirmed COVID-19 case (date of first symptoms), the study database
301 was frozen for the primary analysis, the date subject was unblinded, the date subject received
302 an approved or authorized COVID-19 vaccine, or the date of subject completion/withdrawal
303 from the study. The VE success criterion for the primary efficacy endpoint was defined as a
304 ≥ 50 %-point estimate and a >30 % lower limit of the 95% CI. Assuming the number of cases in
305 each arm followed a Poisson distribution, then conditioning on the total number of cases and
306 the ratio of person-time of follow up, the exact 95% CIs for the incidence rate ratio (IRR), and
307 hence for $VE = 1 - IRR$, was obtained assuming a binomial distribution with mid-P adjustment
308 ⁴⁶. Vaccine efficacy for the secondary endpoints was analyzed using the same methods as for
309 the primary endpoint, except for VE success criterion being defined as $>0\%$ lower limit of the
310 95% CI. Cumulative incidence curves were calculated using the Kaplan-Meier method.

311 Median differences in viral load values measured as \log_{10} copies/mL were compared between
312 subjects who received CoVLP+AS03 or placebo by strain and overall using the Wilcoxon rank-
313 sum test. Viral load values under the detection limit (\log_{10} 2.08) were set to half of that limit.

314

315

316 **Results**

317 *Context in which the study was performed*

318 Unlike many earlier Phase 3 efficacy studies, the current trial was conducted at a time of actual
319 or anticipated roll-out of one or more emergency-use SARS-CoV-2 vaccines. Although the
320 pace and penetration of these roll-out campaigns varied widely across countries and regions, the
321 recruitment of elderly volunteers and those with high-risk comorbidities became progressively
322 more difficult over time, leading to much smaller numbers of participants among healthy older
323 adults and adults with comorbidities than originally planned. Furthermore, as countries/regions
324 enlarged the populations eligible for vaccination, a steadily growing number of enrolled
325 participants in all study populations chose to exercise their Protocol-sanctioned option to be
326 unblinded in order to access a deployed vaccine. This led to a progressive loss of participants in
327 both arms of the study through early withdrawal and unblinding with a growing imbalance
328 between the CoVLP+AS03 and placebo arms of the study that was managed by using person-
329 year denominators to calculate all efficacy outcomes, thus taking into account the accrued
330 amount of follow-up for each participant in the study. These impacts were anticipated in the
331 study design that sought to capture cases as quickly as possible to minimize delays in providing
332 vaccines to placebo recipients and mitigate the risk of withdrawals/unblinding events. Among
333 the important design elements was the use of a single COVID-19-compatible symptom to
334 trigger PCR testing that likely led to early identification of cases as well as the detection of a
335 high proportion of minimally symptomatic cases. Finally, unlike many of the early randomized-
336 controlled trials (RCT) of candidate SARS-CoV-2 vaccines that were confronted with either the
337 ancestral (Wuhan) strain only or a limited spectrum of variants, the current study was
338 performed at a time of active viral evolution and the circulation of multiple variants with
339 increased transmissibility⁴⁷, resistance to vaccine-induced immunity or both (see
340 Supplementary Figure 1).

341

342 *Demographic and baseline clinical characteristics*

343 Participants ≥ 18 years of age were tested for SARS-CoV-2 antibodies at 85 sites in the USA
344 (N=41), Canada (N=14), the United Kingdom (N=11), Brazil (N=7), Mexico (N=7), and
345 Argentina (N=5), using a commercial ELISA that targets the nucleocapsid (N) protein
346 (ElecSys, Roche Diagnostics). Provided the participant had no previous history of virologically
347 confirmed COVID-19, both seronegative and seropositive participants were enrolled.

348 Participant disposition and flow diagram are presented in Figure 1. Participant demographics in
349 the PP set are presented in Table 1 and participant demographics in the ITT set are presented in
350 Supplementary Table S1. Of the 25,170 individuals recruited, 24,141 were randomized (ITT
351 set) and 24,076 received one or more study injections. Of these, 20,090 participants received
352 two full vaccinations as scheduled (PP set): 18,150 healthy adults 18-64 years of age, 109
353 healthy older adults aged 65 years or more (0.4%), and 1,831 adults ≥ 18 years of age with high-
354 risk comorbidities (7.5%) (listed in Supplementary Table S2). In the PP set, 10,060 were male
355 (50.1%) and 10,030 were female (49.9%). The racial distribution, in order of decreasing
356 frequency, was 88.8% White or Caucasian, 7.0% Black or African American, 1.2% Asian,
357 0.2% American Indian or Alaska Native, and $<0.1\%$ Native Hawaiian or Other Pacific Islander.
358 Two percent reported multiple races and $<0.1\%$ reported other or had missing racial data.
359 Overall, 83.3% of participants reported Hispanic or Latinx ethnicity, 16.3% were non-Hispanic
360 or Latinx and 0.4% did not report their ethnicity. The median age was 29. The youngest
361 participant was 18 and the oldest was 86.

362

363 *Efficacy*

364 Up to the cut-off date of August 20th, 2021, a total of 401 possible COVID-19 cases were
365 identified in the study population. Of these, based on time of occurrence relative to vaccination,
366 176 were predicted to potentially contribute to determination of the PVE endpoint.
367 Adjudication confirmed the applicability of 165 of these cases (10 were removed due to
368 unblinding prior to diagnosis of COVID-19 and 1 case was determined not to have met the
369 PVE criteria). The PVE analysis was determined based on these 165 adjudicated cases (ITT set;
370 157 in the PP set).

371 Among the 20,090 participants in the PP set, 118 in the placebo group (9,536 participants) and
372 39 in the CoVLP+AS03 group (10,554 participants) developed COVID-19 ≥ 7 days after
373 receiving the second dose. The incidence rate in the placebo group was 0.179 per 1,000 person-
374 years (95% CI: 0.150, 0.215) and was 0.052 in the CoVLP+AS03 group (95% CI: 0.038,
375 0.071). This corresponds to an overall vaccine efficacy of 71.0% (95% CI: 58.7, 80.0, see
376 Figure 2) irrespective of Day 0 serostatus. In the ITT set of 24,141 participants, 125 in the
377 placebo group (12,067 participants) and 40 in the CoVLP+AS03 group (12,074 participants)
378 developed COVID-19 ≥ 7 days after receiving the second dose. This corresponds to a vaccine
379 efficacy of 69.5% (95% CI: 56.7, 78.8; see Figure 2 for incidence rates). VE success for the

380 primary efficacy endpoint was defined as a $\geq 50\%$ point estimate and a lower limit of the 95%
381 CI $> 30\%$. These primary outcome criteria were met in both the ITT and PP sets.

382 As shown in Figure 3 for the PP set and in Supplementary Table S3 for the ITT set, VE of
383 CoVLP+AS03 was also separately evaluated in healthy participants 18-64 years of age, healthy
384 participants ≥ 65 years of age, and participants ≥ 18 years of age with significant comorbidities.
385 The VE point estimates in the PP set were 70.9% (95% CI: 57.7, 80.4) and 76.8% (95% CI:
386 21.5, 94.8) for healthy adults aged 64 or less and in adults with significant comorbidities,
387 respectively, and 68.9% (95% CI: 55.0, 78.9) and 78.7% (95% CI: 30.2, 95.1) in these
388 populations in the ITT, respectively irrespective of baseline (Day 0) serostatus. There were only
389 two cases of COVID-19 in healthy older adults aged 65 or more, one in the placebo group and
390 one in the CoVLP+AS03 group, precluding accurate assessment of VE in that population.

391 Vaccine efficacy in preventing moderate (*ad hoc* analysis) or severe disease was determined to
392 be 78.1% (95% CI: 53.9, 90.5) in the PP population and 78.8% (95% CI: 55.8, 90.8) in the ITT
393 set. Among subjects who were seronegative at Day 0, the overall VE against moderate-to-
394 severe disease was 84.5% (95% CI: 62.0, 94.7) in the PP set and 86.0% (95% CI: 66.2, 95.1) in
395 the ITT set. There were only 3 severe cases of COVID-19 in the 165 cases used for the PVE
396 analysis (2 hospitalized) and all were in the placebo group. The VE point estimates were
397 determined by gender, race, and baseline (Day 0) serostatus and are presented in Figure 3 (PP
398 set) and in Supplementary Table S3 (ITT set).

399

400 *Variant-Specific Efficacy*

401 Supplementary Figure 1 illustrates the incidence of COVID-19 by variant in the participating
402 countries (colored bars, left Y-axis) as well as the number of participants with COVID-19
403 contributing to the PVE analysis (red lines, right Y-axis). Up to the cut-off date of August 20th,
404 2021, COVID-19 cases included in the PVE analysis were primarily identified in Argentina
405 (n=59), Brazil (n=53), and the United States of America (n=47), and with much smaller
406 numbers in the United Kingdom (n=4) and Canada (n=2).

407 Based on genomic sequences shared via GISAID, the global data science initiative⁴⁸, the
408 primary variants circulating during the study varied widely by country (see Supplemental
409 Figure 1). The Delta and Gamma strains were the dominant strains in Argentina and Brazil with
410 lesser contributions from Alpha and Lambda variants while Alpha and Delta variants

411 dominated in North America and the UK with lesser contribution from the Gamma variant in
412 Canada and the USA.

413 Of the 157 cases included in the per protocol PVE analysis, sequence data are available for 114
414 (72.6%) and a further 21 (13.4%) could not be sequenced due to very low viral copy numbers
415 in the samples. All sequenced strains were either variants of concern (VoC) or variants of
416 interest (VoI). No case included in the PVE analysis was caused by an ancestral (Wuhan) strain
417 virus. The most frequently sequenced variants were Delta (50, 43.9%) and Gamma (52, 45.6%)
418 with fewer numbers of Alpha (5, 4.4%), Mu (4, 3.5%) and Lambda (3, 2.6%) variants. There
419 were no cases caused by Beta or Omicron variants among those infected.

420 As shown in Figure 4, for the PP set, overall vaccine efficacy point estimates were 75.3% (95%
421 CI: 52.8, 87.9) and 88.6% (95% CI: 74.6, 95.6) for the dominant Delta and Gamma variants,
422 respectively, and were 100% with much broader 95% confidence intervals for the small
423 numbers of Alpha (95% CI: 28.0, -na-), Lambda (95% CI: -50.3, -na-), and Mu variants (95%
424 CI: 2.3, -na-). The corresponding point estimates for the ITT set ranged from 74.0% and 87.8%
425 for Delta and Gamma variants respectively to 100% for the other three variants (see
426 Supplemental Table 3).

427 Sequencing success was markedly different between the CoVLP+AS03 (43.6%) and Placebo
428 groups (82.0%) in the PP set (34.6% versus 83.2%, respectively in the ITT set). Analysis of
429 viral loads at the time of diagnosis revealed a >100-fold difference overall between the
430 CoVLP+AS03 and placebo cases (\log_{10} 3.46 versus \log_{10} 5.65 copies/mL, respectively; see
431 Figure 5). Among the PP set, cases for which sequencing failed [i.e.: PCR-positive but
432 Sequence-negative (PCR⁺/Seq⁻)], 14 were in the CoVLP+AS03 group and 7 were in the
433 placebo group. For these PCR⁺/Seq⁻ cases, the median viral load was at or below the limit of
434 detection of the assay used (120 copies/mL) while the median viral load for the cases from
435 which sequence information could be obtained was >500,000 copies/mL. Viral loads in the
436 breakthrough Delta and Gamma cases were 42-fold and 269-fold lower in the CoVLP+AS03
437 group compared to the placebo group (\log_{10} 3.65 versus \log_{10} 5.27 and \log_{10} 3.78 versus \log_{10}
438 6.21, respectively; See Figure 5). A similar trend of markedly lower viral loads was observed in
439 breakthrough cases classified as either mild (\log_{10} 3.56 versus \log_{10} 5.70 or 138-fold) or
440 moderate (\log_{10} 2.85 versus \log_{10} 5.48 or 426-fold) in the CoVLP+AS03 and placebo groups,
441 respectively.

442

443 *Tolerability and Safety*

444 Solicited AEs up to 7 days after first or second injection for both CoVLP+AS03 and placebo
445 recipients were collected and analyzed for 7,819 participants (4,136 CoVLP+AS03 recipients
446 and 3,683 placebo recipients) and are shown in Figure 6. Overall, both solicited local and
447 systemic AEs were predominantly mild to moderate in intensity and transient in nature, lasting
448 1-3 days on average.

449 As shown in Supplementary Table S4, more participants who received the CoVLP+AS03
450 (3,819; 92.3%) than those who received placebo (1,677; 45.5 %) reported local solicited AEs
451 after receiving first and/or second treatment; driven largely by pain at injection site. None of the
452 solicited local AEs were potentially life-threatening (Grade 4). The incidence of Grade 2 and
453 Grade 3 local AEs was higher after the second vaccination. Severe (Grade 3) solicited local
454 AEs were reported by 33 (0.8%) and 85 (2.1%) after the first and second injections respectively
455 among those who received CoVLP+AS03, and 2 (<0.1%) and 1 (<0.1%) respectively among
456 the participants who received placebo.

457 As shown in Supplementary Table S5, similar to local solicited AEs, solicited systemic AEs
458 were also more common in the participants who received CoVLP+AS03 (3,612; 87.3%)
459 compared to those who received placebo (2,394; 65.0%) after receiving first and/or second
460 treatment. Both the frequencies and intensities of these events increased after the second dose
461 compared to the first (Supplementary Table S5). The more common systemic AEs in both
462 groups were headache, fatigue, myalgia, and a general feeling of discomfort. Fever was
463 reported in 1.1% after the first dose and was reported by 8.6% after the second dose in
464 CoVLP+AS03 recipients. There were 42 participants (1.0%) with Grade 3 solicited systemic
465 AEs after the first injection and 129 (3.1%) after the second injection in the CoVLP+AS03
466 group, and 24 (0.7%) and 20 (0.5%) in the placebo group after the first and second injections
467 respectively. Three participants reported Grade 4 systemic solicited AEs, 2 (<0.1%) in the
468 CoVLP+AS03 group and 1 (<0.1%) in the placebo group; all occurred after the second
469 injection.

470 For the analysis of the unsolicited AEs, safety data available from all participants in the SAS
471 were included. The study measured the occurrence, intensity, and relationship of unsolicited
472 AEs for 21 days after each dose, while SAEs, MAAEs, AEs leading to withdrawal, AESIs
473 (including VAED/VAERD, anaphylaxis and severe allergic reactions, pIMDs), and deaths were
474 monitored for 21 days after each dose (Supplementary Table S6) and then from day 43 to day

475 201 (Supplementary Table S7). The incidence of unsolicited AEs after receiving first and/or
476 second treatment was slightly higher in CoVLP+AS03 recipients than in placebo recipients
477 (22.7% vs 20.4% during the 21 days after vaccination, and 4.2% vs 4.0% during the 43 to 201
478 days after vaccination). Unsolicited preferred term (PT) events with a frequency $\geq 1\%$ after
479 receiving first and/or second vaccination are presented in Supplementary Table S8.

480 The frequency of SAEs reported in subjects was similar between vaccine (24: 0.2%) and
481 placebo recipients (16: 0.1%) up to 21 days after receiving first and/or second treatment.
482 Between Day 43 and Day 201, SAEs were reported by 19 (0.2%) and 22 (0.2%) of the
483 participants in the CoVLP+AS03 and placebo groups, respectively after receiving first and/or
484 second treatment. No SAE was assessed as related to the investigational product in
485 CoVLP+AS03 group and one subject in the placebo group reported 2 related SAEs (aortic
486 thrombosis and peripheral artery thrombosis). No significant imbalance or safety concern was
487 noted in MAAEs, AESIs, AEs leading to withdrawal, deaths, or specific AEs reported after
488 vaccination with currently authorized vaccines (Bell's palsy, myocarditis, thrombotic events,
489 etc. ⁴⁹; see Supplemental Table S9). There were no deaths related to the vaccine in the study.

490 **Discussion**

491 Despite the challenges of conducting a Phase 3, placebo-controlled vaccine efficacy study in
492 the face of international vaccination roll-out campaigns and rapid viral evolution,
493 CoVLP+AS03 met the primary efficacy endpoint of the study. Two doses of CoVLP+AS03
494 delivered 21 days apart provide substantial protection against symptomatic COVID-19 caused
495 by a range of SARS-CoV-2 variants including Alpha, Delta, Gamma, Lambda, and Mu.

496 The vaccine provided >70% protection against symptomatic COVID-19 of any severity in a
497 diverse adult population including those with high-risk comorbidities irrespective of baseline
498 serostatus. While vaccine efficacy in healthy adults over the age of 65 could not be determined
499 due to ethical considerations that limited the number of older adults in the study, two doses of
500 CoVLP+AS03 were previously shown to induce a neutralizing antibody response in healthy
501 older adults that is indistinguishable from that seen in healthy adults⁴¹, suggesting that
502 CoVLP+AS03 may provide comparable protection across the adult age range.

503 Prevention of severe disease and hospitalization, both to improve health outcomes and to
504 alleviate health care resource constraints, remains a critical objective of national vaccination
505 campaigns. While there were only two PP cases of severe disease in the trial and three in the
506 ITT set (two of which required hospitalization), all were in the placebo group. Furthermore, in
507 an *ad hoc* analysis, overall vaccine efficacy against combined moderate-severe disease was
508 78.1%. Since the concentration of virus in the upper respiratory tract is a major determinant of
509 sequencing success, the fact that the infecting strain could be identified in only 43.6% of the
510 CoVLP+AS03 cases compared to 82% of the Placebo cases suggested that the viral loads in the
511 PCR+Seq⁻ ‘breakthrough’ cases in the vaccinated group would be low and that these cases
512 would be mild, both of which proved to be true. Although completely asymptomatic individuals
513 can have high viral loads in their upper respiratory tracts and there are conflicting data on the
514 relationship between viral load at diagnosis and disease progression/severity, many groups
515 have demonstrated that viral load in the upper respiratory tract can be a predictor of disease
516 severity in COVID-19 patients⁵⁰⁻⁵³. All of the PCR+Seq⁻ cases in current study were
517 adjudicated to be mild and interestingly, the viral loads in these cases in either group were at or
518 near the limit of detection of the RT-qPCR assay used (\log_{10} 2.08 copies/mL) with a mean value
519 ~3715x lower than the PCR+Seq⁺ cases in the placebo group (\log_{10} 5.65 copies/mL: Figure 5).
520 These observations suggest that the overall VE point estimate for CoVLP+AS03 was, at least to
521 some extent, drawn down by mild, PCR+Seq⁻ breakthrough cases with very low viral loads.
522 Indeed, the VE point estimate for the very mild, PCR+Seq⁻ cases was -75.3% (95% CI: -364.0,
19

523 28.6) which explains the difference between the overall VE estimate (71%) and both the strain-
524 specific estimates (75.3-100%) and the estimate for the prevention of moderate or severe
525 disease (78.1%). A large real-world evidence (RWE) study in the UK recently demonstrated the
526 dilutive effect of low viral load cases on VE estimates for both mRNA and Adenovirus-
527 vectored vaccines⁵⁴. During the period when the Delta variant predominated, for example, the
528 efficacy of an mRNA vaccine for high viral load disease was 86% (Ct values <30) but fell to
529 71% for low viral load illness (Ct values ≥30). A unique feature of the current study, which
530 helped identify cases as quickly as possible in the rapidly evolving pandemic, was the use of a
531 single COVID-19-compatible symptom to trigger PCR testing. While this undoubtedly led to
532 faster case accrual, it is likely that the use of a single symptom trigger may have led to the
533 inclusion of a disproportionate number of very mild cases, and consequently to an
534 underestimation of overall PVE relative to studies that used more restrictive clinical criteria to
535 trigger swab collection.

536 Analysis of viral load over time after diagnosis was included in this study as a secondary
537 outcome to look at the impact of vaccination on the magnitude and duration of viral shedding.
538 However, an initial observation of a 2-fold difference in sequencing success between the
539 CoVLP+AS03 and placebo cases suggested there might be important differences in the viral
540 load at diagnosis and prompted an immediate analysis of these results. To our knowledge, this
541 is the first Phase 3 RCT that has considered viral load as a parameter in the characterization of
542 cases. This analysis in different subgroups revealed that breakthrough PCR⁺/Seq⁻ cases in the
543 CoVLP+AS03 group had between 42- and 420-fold less virus in the nasal passages at the time
544 of diagnosis compared to the placebo group. Although this represents only a single time-point
545 in the evolution of each case, follow-up swabs were collected every other day from these
546 subjects while symptoms persisted to address one of the study's secondary outcomes (i.e.:
547 duration and magnitude of viral shedding). Analysis of these swabs is underway but, given the
548 striking initial differences in viral load at the time of diagnosis, consistent with recent analysis
549 examining viral load in Adenoviral vector- and mRNA- vaccinated individuals⁵⁵, it seems
550 likely that vaccination with CoVLP+AS03 had significant virologic impact in the breakthrough
551 cases with possible implications for both disease severity and reduced transmission.

552 While the recently-emerged Omicron variant threatens to spread rapidly, the dominant variants
553 at the time this study was conducted were Alpha and Delta in North America and the UK, and
554 Gamma and Delta in South America (Supplementary Figure 1) with lesser contributions from
555 Lambda and Mu variants. Like all other currently deployed vaccines, CoVLP+AS03 was

556 designed to target the ancestral (Wuhan) strain of SARS-CoV-2 but not a single case of
557 COVID-19 caused by this strain was identified in the current study. This trial, along with
558 Clover’s recently announced global study and Novavax’s regional studies, are among the first
559 Phase 3 RCTs to be confronted by a variant-dominant environment ^{17,56}. Although vaccines
560 developed during the first waves of the pandemic reported vaccine efficacies as high as 95%
561 ^{7,57}, the more recent RCTs and RWE studies performed during successive variant-dominated
562 periods have consistently demonstrated that overall vaccine efficacy is substantially reduced
563 compared to the Wuhan-era, although efficacy against the most severe forms of COVID-19 has
564 generally been preserved. A recent meta-analysis of vaccine efficacy against the Delta variant
565 by platform ¹⁴ suggested performance of 59% (95% CI: 26.1, 100) for inactivated vaccines,
566 67.7% (95% CI: 62.3, 72.5) for Adenovirus-vector vaccines, and 77.7% (95% CI: 68.22, 88.59)
567 for mRNA-based vaccines, possibly attributable to increased viral replication and
568 transmissibility of this variant, as well as immune-evasive mutations in the spike protein ¹³.
569 Although the results from RCTs and RWE studies should only be compared with caution and
570 most RWE studies are influenced by both strain and time post-vaccination ^{15,58}, the context in
571 which vaccines are currently ‘asked to perform’ has clearly changed and the overall VE for
572 CoVLP+AS03 of 71% (84.5% in baseline seronegative individuals) with strain-specific VE
573 ranging from 75.3-100% seen in the current study appears to compare favorably to the currently
574 reported effectiveness of other candidates and deployed vaccines ^{13-15,17,56,59}. This is particularly
575 true since CoVLP+AS03 was challenged in this study by a range of strains with known
576 immune-evasive mutations, including Delta, Gamma and Mu variants ^{60,61}. The challenges
577 faced by CoVLP+AS03 in the on-going Phase 3 study continue with the rapid emergence of the
578 Omicron variant. Active surveillance for cases will continue until the trial is terminated per-
579 Protocol when the placebo recipients are offered vaccination or release from their study
580 commitments and VE of CoVLP+AS03 against this most recent VoC will be calculated.

581 Overall, CoVLP+AS03 was well-tolerated and the safety profile in the Phase 3 portion of the
582 Phase 2/3 study largely confirmed observations of the smaller Phase 1 study ⁴² and the Phase 2
583 portion ⁴¹. Most vaccine recipients reported at least one local or systemic adverse event, the
584 large majority of these events were Grade 1-2 and transient and consistent with past reports of
585 AS03-adjuvanted influenza vaccines ⁴⁰. The safety profile was generally comparable to recently
586 reported solicited and unsolicited safety data for other deployed and candidate SARS-CoV-2
587 vaccines ^{7,57,62,63}. Although 41.8% of participants reported mild-to-moderate and transient chills
588 after the second dose, a documented fever was largely absent after the first dose and only

589 reported by 8.6% of the participants after the second dose. As generally observed for COVID-
590 19 vaccines ^{7,57,62,63}, there was an increase in both the frequency and severity of solicited AEs
591 after the second dose compared to the first dose. No safety concerns related to vaccination
592 identified during the study up to the safety data cut-off date of October 25th, 2021. Although the
593 number of participants exposed to the CoVLP+AS03 in the clinical development to date
594 remains relatively small (~13,000 in the Phase 1, 2 and 3 studies) with a relatively short period
595 of follow-up post vaccination, it is nonetheless reassuring that there has been no suggestion of
596 VAED in either a large primate challenge study ⁶⁴ or in the clinical trials ^{41,42}. There were no
597 episodes of anaphylaxis or severe allergic reactions reported in the study. It is also reassuring
598 that no imbalance of myocarditis or thrombotic events was observed, and all reported SAEs
599 were considered unrelated to CoVLP+AS03 by the investigators.

600 Although the past 24 months have witnessed an unprecedented growth in vaccine science with
601 the introduction and large-scale deployment of several SARS-CoV-2 vaccines produced using
602 new platforms, this remarkable period of vaccine innovation has not yet run its course. If
603 CoVLP+AS03 is licensed, it will be the first plant-based vaccine approved for human use and
604 one of only a small number of plant-produced biopharmaceuticals ⁶⁵. It may also be the first
605 VLP vaccine for SARS-CoV-2, bringing the potential advantages of this vaccine technology to
606 the fight against COVID-19 ²⁴. The plant-based manufacturing platform has a number of
607 natural advantages since it can theoretically be introduced across a wide range of scales from a
608 modular, country-sized unit to a global manufacturing facility. Although the downstream
609 processing and purification procedures are similar across all recombinant protein vaccine
610 platforms, the upstream processes for plant-produced vaccines are based on sunlight and tightly
611 controlled water and growth substrate to support the living plant ‘bioreactor’. As a result, this
612 platform has the potential to promote distributive vaccine (and other biopharmaceutical)
613 production rather than the current highly centralized production model that has contributed to
614 the striking imbalances in the global distribution of SARS-CoV-2 vaccines ⁶⁶⁻⁶⁸. Like other
615 VLP vaccines, CoVLP is stable at refrigerator temperatures (2-8°C), making it easier to use in
616 small and remote communities in resource-rich countries as well as in low- and middle-income
617 countries than several of the currently deployed vaccines ⁶⁶. Although much attention has been
618 devoted to the ‘new’ vaccine platforms like the mRNA and Adenovirus-vectored vaccines,
619 there is still clearly a place in the fight against SARS-CoV-2 for more traditional inactivated
620 virion and protein+adjuvant vaccines ⁶⁹. In particular, protein+adjuvant vaccines may be
621 attractive to those who want to be vaccinated but have objecting beliefs or concerns regarding

622 platforms associated with currently available vaccines ²³. Protein+adjuvant vaccines may also
623 play an important role as an option to boost the responses initiated by other primary vaccination
624 strategies ^{59,70}.

625 Like any Phase 3 study done under pandemic conditions, the current trial had limitations, the
626 most obvious of which are the limited number of older adults and smaller proportion of adults
627 with comorbidities who were able to participate due to on-going vaccine roll-out programs and
628 the relatively short period of follow-up due to the event-driven design. However,
629 immunogenicity data from the Phase 2 portion of the current study demonstrated strong
630 neutralizing antibody and cellular responses in all three study populations after two doses of
631 CoVLP+AS03 ⁴¹, and 6-month follow-up of CoVLP+AS03 recipients in the preceding Phase 1
632 study demonstrated that both humoral and cellular responses were durable ⁷¹. Although
633 relatively few severe cases (three in the ITT set and two in the PP set) and two hospitalizations
634 occurred in this study, all fell into the placebo arm and the overall efficacy against moderate
635 and severe disease combined was 78.1% and 78.8% in the ITT and PP sets, respectively,
636 suggesting that protection against the more severe manifestations of COVID-19 caused by a
637 range of variants was substantial. This study is still ongoing, and a wide range of secondary
638 outcomes will be reported as the data become available.

639 The primary vaccine efficacy and safety data presented here demonstrate that substantial
640 protection against a range of VoC can be provided by two doses of CoVLP+AS03. New cases
641 continue to be identified in the ongoing Phase 3 study and the efficacy of this new candidate
642 vaccine against the recently-emerged Omicron variant will be determined in the coming
643 months. Overall, the vaccine was generally well-tolerated and no safety signals were detected
644 during the study. Once approved by regulators, this more traditional protein+adjuvant vaccine
645 produced using the novel plant-based platform may be able to make an important contribution
646 to the global struggle against the increasingly complex family of SARS-CoV-2 viruses.

647 **Author Contributions**

648 All authors contributed significantly to the submitted work. KJH, GH, AIM, AM, JA, JN, ST,
649 MAD, YK, BJW contributed to all aspects of the clinical study from conception to completion.
650 PG, SP, KB, LD, SL, PS, IB, AL, JP, JJW, EP, LT, ASE, LHM contributed to design and
651 execution of the study as well as analysis and presentation of the data. GPM, RSD, EV, FR,
652 RGW, GW, HA, CJ, TB, MAC, MK, FR, FPP contributed to design and oversight of the
653 conduct of the study. All authors contributed to critical review of the data and the writing of the
654 manuscript. All Medicago authors had full access to the data. YK, MAD, BJW made the final
655 decision to submit the manuscript.

656

657 **Acknowledgements**

658 The authors acknowledge all the volunteers who participated in the study as well as the site
659 investigators and their staff for conducting the studies with a high degree of professionalism.
660 The authors also wish to acknowledge all the employees and contractors of Medicago and GSK
661 who supported the study, directly or indirectly. With regard to supplementary Figure 1, we
662 gratefully acknowledge all data contributors (the authors, their originating laboratories
663 responsible for obtaining the specimens, and the submitting laboratories) for generating the
664 genetic sequence and metadata and sharing it via the GISAID Initiative, on which this figure is
665 based.

666

667 **Funding Statement**

668 The study was sponsored by Medicago Inc.

669

670 **Data Availability**

671 Medicago Inc. is committed to providing access to anonymized data collected during the trial
672 that underlie the results reported in this article, at the end of the clinical trial, which is currently
673 scheduled to be 1 year after the last participant is enrolled, unless granted an extension.
674 Medicago Inc. will collaborate with its partner (GlaxoSmithKline, Wavre, Belgium) on such
675 requests before disclosure. Proposals should be directed to wardb@medicago.com or
676 daoustma@medicago.com. To gain access, data requestors will need to sign a data access
677 agreement and access will be granted for non-commercial research purposes only.

678

679 **Conflict of Interest**

680 During the period of the study KJH, PG, GH, AIM, SP, KB, JA, IB, JD, NC, MC, JJW, NL,
681 SL, AL, AM, EP, JP, PS, AS, LT, JN, MAD, ST, YK, BJW were either employees of
682 Medicago Inc. or received salary support from Medicago Inc. TB, MAC, MK, FR are
683 employed by the GlaxoSmithKline (GSK) group of companies and hold restricted shares in the
684 group of companies. LHM received compensation from Medicago as a consultant.

685

686 **Figure Legends**

687 **Figure 1**

688 **Trial Profile – Participant Disposition**

689 Data cut-off for primary efficacy analysis occurred on August 20th, 2021. The intention-to-treat
690 (ITT) population was comprised of participants in the randomized population who had no
691 virologic evidence of COVID-19 prior to injection. The per-protocol (PP) population included
692 participants who received two doses and had no major protocol deviations. The safety analysis
693 set (SAS) included all participants who received at least one injection. For details on participant
694 demographics, see Table 1.

695

696 **Figure 2**

697 **Cumulative Incidence of COVID-19 in CoVLP+AS03 Vaccinated and Placebo Control**
698 **Study Participants**

699 Cumulative incidence of adjudicated COVID-19 events in the per protocol (a) and intention to
700 treat (b) populations starting 7 days after the second vaccination. Red lines indicate placebo
701 treatment and blue lines indicate CoVLP+AS03 treatment. Vaccine efficacy was calculated as
702 $100 \times (1 - \text{incidence rate ratio})$ where the incidence rate ratio is defined as the ratio of person-
703 years rate of COVID-19 cases in the CoVLP+AS03 group relative to the COVID-19 cases in
704 the placebo group. Events (tick marks) are COVID-19 cases from PCR-positive
705 nasopharyngeal swabs independently confirmed and adjudicated by an IDMC sub-committee.

706

707 **Figure 3**

708 **Subgroup Analysis of Vaccine Efficacy of CoVLP+AS03 to Prevent COVID-19**

709 Efficacy of CoVLP+AS03 vaccine in preventing COVID-19 in various subgroups within the
710 per protocol population. Subgroup vaccine efficacy was calculated as $100 \times (1 - \text{incidence rate}$
711 $\text{ratio})$ where the incidence rate ratio is defined as the ratio of person-years rate of COVID-19
712 cases in the CoVLP+AS03 group relative to the COVID-19 cases in the placebo for each
713 subgroup analyzed. Yrs: years; 95% CI: 95% confidence interval; NA: not applicable

714

715

716 **Figure 4**

717 **Vaccine Efficacy by Variant**

718 Efficacy of CoVLP+AS03 vaccine in preventing COVID-19 by variant within the per protocol
719 population. Vaccine efficacy by variant was calculated as $100 \times (1 - \text{incidence rate ratio})$ where
720 the incidence rate ratio is defined as the ratio of person-years rate of COVID-19 cases in the
721 CoVLP+AS03 group relative to the COVID-19 cases in the placebo for each variant. Yrs:
722 years; 95% CI: 95% confidence interval; NA: not applicable

723

724 **Figure 5**

725 **Viral load**

726 Mean viral loads, presented in log virus copies per mL, are provided for both placebo and
727 CoVLP+AS03 recipients by subgroup. Numbers in parentheses indicate 1) the number of
728 individuals in each group, and 2) standard deviation. To the right, symbols indicate mean log
729 virus copy per mL (blue circles: CoVLP+AS03, green squares: placebo) and horizontal bars
730 indicate standard deviation. P-values as determined by Wilcoxon rank-sum test indicate
731 differences between the placebo and CoVLP+AS03 recipients by subgroup. All analysis is
732 based on the intention to treat (ITT) population set. NE: not estimable.

733

734 **Figure 6**


735 **Solicited Local and Systemic AEs during the 7-Days After the First or Second Doses in**
736 **both study groups (CoVLP+AS03 vs placebo)**

737 Participants were monitored for solicited local and systemic Adverse Events (AEs) from the
738 time of vaccination through 7 days after vaccine administration. Participants who reported no
739 AEs or for whom Serious Adverse Events (SAE) data are lacking make up the remainder of the
740 100% calculation (not shown). For each category, AEs are classified as follows: Grade 1 =
741 Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially life threatening. If a
742 participant had the same AE but with different grades, the highest grade was reported. If any of
743 the solicited AEs persisted beyond Day 7 after vaccination, it was recorded as an unsolicited
744 AE. Fever was defined as oral temperature $\geq 38.0^\circ\text{C}$.

745 **Figures**


746 **Figure 1 CONSORT Flow Diagram**

747




748

749 **Figure 2 Cumulative Incidence Curves from Seven Days Post Second Injection**



750


751 **Figure 3 Efficacy by Subgroup**



752


753 **Figure 4 Efficacy by Circulating Variant**

754




755

756 **Figure 5 Viral Load**



757

758 **Figure 6 Solicited Adverse Events**



759

760 **Table 1: Summary of Demographics in the Per Protocol Set (NCT04636697)**

761 ‘N’ is the number of participants in a population, while ‘n’ represents the number of
 762 participants in a category. Race and/or ethnic group were reported by the participants, who
 763 could have listed more than one category. SD: Standard deviation; Min.: Minimum; Max.:
 764 Maximum.

	Healthy Adults		Older Adults (65+)		Adults with Comorbidities		All Participants	
	CoVLP + AS03	Placebo	CoVLP + AS03	Placebo	CoVLP + AS03	Placebo	CoVLP + AS03	Placebo
Participants (N)	9,541	8,609	55	54	958	873	10,554	9,536
Sex, n (%)								
Male	4,764 (49.9)	4,324 (50.2)	30 (54.5)	27 (50.0)	474 (49.5)	441 (50.5)	5,268 (49.9)	4,792 (50.3)
Female	4,777 (50.1)	4,285 (49.8)	25 (45.5)	27 (50.0)	484 (50.5)	432 (49.5)	5,286 (50.1)	4,744 (49.7)
Race, n (%)								
American Indian/ Alaska Native	21 (0.2)	15 (0.2)	0	0	1 (0.1)	4 (0.5)	22 (0.2)	19 (0.2)
Asian	116 (1.2)	94 (1.1)	1 (1.8)	0	9 (0.9)	7 (0.8)	126 (1.2)	101 (1.1)
Black/ African American	449 (4.7)	434 (5.0)	7 (12.7)	9 (16.7)	101 (10.5)	97 (11.1)	557 (5.3)	540 (5.7)
Multiple	177 (1.9)	183 (2.1)	1 (1.8)	0	22 (2.3)	17 (1.9)	200 (1.9)	200 (2.1)
Native Hawaiian or Other Pacific Islander	19 (0.2)	14 (0.2)	0	0	2 (0.2)	4 (0.5)	21 (0.2)	18 (0.2)
White or Caucasian	8,720 (91.4)	7,835 (91.0)	45 (81.8)	45 (83.3)	817 (85.3)	743 (85.1)	9,582 (90.8)	8,623 (90.4)
Other	1 (<0.1)	1 (<0.1)	0	0	0	0	1 (<0.1)	1 (<0.1)
Not Reported	35 (0.4)	29 (0.3)	0	0	5 (0.5)	1 (0.1)	40 (0.4)	30 (0.3)
Ethnicity, n (%)								
Hispanic or Latinx	8,076 (84.6)	7,171 (83.3)	13 (23.6)	22 (40.7)	761 (79.4)	698 (80.0)	8,850 (83.9)	7,891 (82.7)
Not Hispanic or Latinx	1,428 (15.0)	1,409 (16.4)	42 (76.4)	32 (59.3)	196 (20.5)	171 (19.6)	1,666 (15.8)	1,612 (16.9)
Not Reported/ Specified	37 (0.4)	29 (0.3)	0	0	1 (0.1)	4 (0.5)	38 (0.4)	33 (0.3)
Age at consent (years)								
Mean (SD)	31.8 (10.98)	31.9 (11.13)	69.9 (4.30)	69.8 (5.09)	38.7 (13.74)	40.2 (14.37)	32.6 (11.72)	32.9 (12.01)
Median	29.0	29.0	69.0	68.0	37.0	39.0	29.0	29.0
Min, Max	18, 64	18, 64	65, 80	65, 86	18, 82	18, 86	18, 82	18, 86

765
 766

767 **References**

- 768 1. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new
769 coronavirus of probable bat origin. *Nature* 2020;579:270-3.
- 770 2. WHO Coronavirus Disease (COVID-19) Dashboard. 2021. (Accessed January 12th,
771 2022, at <https://covid19.who.int/>.)
- 772 3. Funk CD, Laferriere C, Ardakani A. Target Product Profile Analysis of COVID-19
773 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective *Viruses* 2021;13.
- 774 4. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain
775 bound to the ACE2 receptor. *Nature* 2020;581:215-20.
- 776 5. Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells.
777 *Nature Reviews Molecular Cell Biology* 2021.
- 778 6. Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations
779 and immune escape. *Nat Rev Microbiol* 2021;19:409-24.
- 780 7. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA
781 Covid-19 Vaccine. *N Engl J Med* 2020;383:2603-15.
- 782 8. Moghadas SM, Vilches TN, Zhang K, et al. The impact of vaccination on COVID-19
783 outbreaks in the United States. *medRxiv* 2021.
- 784 9. Subbarao K. The success of SARS-CoV-2 vaccines and challenges ahead. *Cell Host*
785 *Microbe* 2021;29:1111-23.
- 786 10. Vashi AP, Coiado OC. The future of COVID-19: A vaccine review. *J Infect Public*
787 *Health* 2021;14:1461-5.
- 788 11. Castiello T, Georgiopoulos G, Finocchiaro G, et al. COVID-19 and myocarditis: a
789 systematic review and overview of current challenges. *Heart Fail Rev* 2021:1-11.
- 790 12. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic
791 Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. *N Engl J Med* 2021;384:2092-101.
- 792 13. Bian L, Gao Q, Gao F, et al. Impact of the Delta variant on vaccine efficacy and
793 response strategies. *Expert Rev Vaccines* 2021;20:1201-9.
- 794 14. Cai C, Liu Y, Zeng S, Shen H, Han Y. The efficacy of COVID-19 vaccines against the
795 B.1.617.2 (delta) variant. *Mol Ther* 2021;29:2890-2.
- 796 15. Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-
797 19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and
798 variants of concern: A narrative review. *Clin Microbiol Infect* 2021.
- 799 16. Goldberg Y, Mandel M, Bar-On YM, et al. Waning Immunity after the BNT162b2
800 Vaccine in Israel. *N Engl J Med* 2021.
- 801 17. Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine
802 against the B.1.351 Variant. *N Engl J Med* 2021;384:1899-909.
- 803 18. Pegu A, O'Connell SE, Schmidt SD, et al. Durability of mRNA-1273 vaccine-induced
804 antibodies against SARS-CoV-2 variants. *Science* 2021;373:1372-7.
- 805 19. Thomas SJ, Moreira ED, Jr., Kitchin N, et al. Safety and Efficacy of the BNT162b2
806 mRNA Covid-19 Vaccine through 6 Months. *N Engl J Med* 2021;385:1761-73.
- 807 20. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2
808 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
809 *Lancet* 2021.
- 810 21. Peacocke EF, Heupink LF, Frønsdal K, Dahl EH, Chola L. Global access to COVID-19
811 vaccines: a scoping review of factors that may influence equitable access for low and middle-
812 income countries. *BMJ Open* 2021;11:e049505.
- 813 22. Wouters OJ, Shadlen KC, Salcher-Konrad M, et al. Challenges in ensuring global
814 access to COVID-19 vaccines: production, affordability, allocation, and deployment. *Lancet*
815 2021;397:1023-34.

- 816 23. Aw J, Seng JJB, Seah SSY, Low LL. COVID-19 Vaccine Hesitancy-A Scoping
817 Review of Literature in High-Income Countries. *Vaccines (Basel)* 2021;9.
- 818 24. Roldão A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in
819 vaccine development. *Expert Rev Vaccines* 2010;9:1149-76.
- 820 25. Landry N, Ward BJ, Trépanier S, et al. Preclinical and clinical development of plant-
821 made virus-like particle vaccine against avian H5N1 influenza. *PLoS One* 2010;5:e15559.
- 822 26. Pillet S, Aubin É, Trépanier S, et al. Humoral and cell-mediated immune responses to
823 H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE
824 adjuvants in a Phase 2 clinical trial. *npj Vaccines* 2018;3:3.
- 825 27. Pillet S, Couillard J, Trépanier S, et al. Immunogenicity and safety of a quadrivalent
826 plant-derived virus like particle influenza vaccine candidate—Two randomized Phase II clinical
827 trials in 18 to 49 and ≥ 50 years old adults. *PLoS One* 2019;14:e0216533.
- 828 28. Pillet S, Racine T, Nfon C, et al. Plant-derived H7 VLP vaccine elicits protective
829 immune response against H7N9 influenza virus in mice and ferrets. *Vaccine* 2015;33:6282-9.
- 830 29. Ward BJ, Makarkov A, Séguin A, et al. Efficacy, immunogenicity, and safety of a
831 plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and
832 older adults (≥ 65 years): two multicentre, randomised phase 3 trials. *The Lancet* 2020.
- 833 30. D'Aoust MA, Couture MM, Charland N, et al. The production of hemagglutinin-based
834 virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. *Plant*
835 *Biotechnol J* 2010;8:607-19.
- 836 31. Morel S, Didierlaurent A, Bourguignon P, et al. Adjuvant System AS03 containing α -
837 tocopherol modulates innate immune response and leads to improved adaptive immunity.
838 *Vaccine* 2011;29:2461-73.
- 839 32. Burny W, Callegaro A, Bechtold V, et al. Different Adjuvants Induce Common Innate
840 Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in
841 Humans. *Front Immunol* 2017;8:943.
- 842 33. De Mot L, Bechtold V, Bol V, et al. Transcriptional profiles of adjuvanted hepatitis B
843 vaccines display variable interindividual homogeneity but a shared core signature. *Sci Transl*
844 *Med* 2020;12.
- 845 34. Howard LM, Goll JB, Jensen TL, et al. AS03-Adjuvanted H5N1 Avian Influenza
846 Vaccine Modulates Early Innate Immune Signatures in Human Peripheral Blood Mononuclear
847 Cells. *J Infect Dis* 2019;219:1786-98.
- 848 35. Arunachalam PS, Walls AC, Golden N, et al. Adjuvanting a subunit COVID-19
849 vaccine to induce protective immunity. *Nature* 2021;594:253-8.
- 850 36. Khurana S, Coyle EM, Manischewitz J, et al. AS03-adjuvanted H5N1 vaccine
851 promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1
852 neutralization, but not H1N1 cross-subtype neutralization. *npj Vaccines* 2018;3:40.
- 853 37. Leroux-Roels I, Borkowski A, Vanwolleghe T, et al. Antigen sparing and cross-
854 reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a
855 randomised controlled trial. *Lancet* 2007;370:580-9.
- 856 38. Moris P, van der Most R, Leroux-Roels I, et al. H5N1 influenza vaccine formulated
857 with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. *J Clin*
858 *Immunol* 2011;31:443-54.
- 859 39. Budroni S, Buricchi F, Cavallone A, et al. Antibody avidity, persistence, and response
860 to antigen recall: comparison of vaccine adjuvants. *npj Vaccines* 2021;6:78.
- 861 40. Cohet C, van der Most R, Bauchau V, et al. Safety of AS03-adjuvanted influenza
862 vaccines: A review of the evidence. *Vaccine* 2019;37:3006-21.
- 863 41. Gobeil P, Pillet S, Séguin A, et al. Interim Report of a Phase 2 Randomized Trial of a
864 Plant-Produced Virus-Like Particle Vaccine for Covid-19 in Healthy Adults Aged 18-64 and
865 Older Adults Aged 65 and Older. *medRxiv* 2021:2021.05.14.21257248.

- 866 42. Ward BJ, Gobeil P, Séguin A, et al. Phase 1 randomized trial of a plant-derived virus-
867 like particle vaccine for COVID-19. *Nature Medicine* 2021;27:1071-8.
- 868 43. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell*
869 2021;184:861-80.
- 870 44. Lu X, Wang L, Sakthivel SK, et al. US CDC Real-Time Reverse Transcription PCR
871 Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2. *CDC- Emerging*
872 *Infectious Diseases* 2000;26.
- 873 45. FDA. Guidance for Industry: COVID-19: Developing Drugs and Biological Products
874 for Treatment or Prevention. 2020.
- 875 46. Rothman KJ, Greenland S, TL L. Chapter 14. *Modern Epidemiology* 3rd ed.
876 Philadelphia: Lippincott Williams & Wilkins; 2008.
- 877 47. Rosenberg ES, Dorabawila V, Easton D, et al. COVID-19 Vaccine Effectiveness by
878 Product and Timing in New York State. *medRxiv* 2021:2021.10.08.21264595.
- 879 48. Khare S, Gurry C, Freitas L, et al. GISAID's Role in Pandemic Response. *China CDC*
880 *Wkly* 2021;3:1049-51.
- 881 49. Center for Disease Control and Prevention: Reported Adverse Events. 2021. 2021, at
882 <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html>.)
- 883 50. de la Calle C, Lalueza A, Mancheño-Losa M, et al. Impact of viral load at admission on
884 the development of respiratory failure in hospitalized patients with SARS-CoV-2 infection. *Eur*
885 *J Clin Microbiol Infect Dis* 2021;40:1209-16.
- 886 51. El Zein S, Chehab O, Kanj A, et al. SARS-CoV-2 infection: Initial viral load (iVL)
887 predicts severity of illness/outcome, and declining trend of iVL in hospitalized patients
888 corresponds with slowing of the pandemic. *PLoS One* 2021;16:e0255981.
- 889 52. Kwon JS, Kim JY, Kim MC, et al. Factors of Severity in Patients with COVID-19:
890 Cytokine/Chemokine Concentrations, Viral Load, and Antibody Responses. *Am J Trop Med*
891 *Hyg* 2020;103:2412-8.
- 892 53. Wang Y, Zhang L, Sang L, et al. Kinetics of viral load and antibody response in
893 relation to COVID-19 severity. *J Clin Invest* 2020;130:5235-44.
- 894 54. Pouwels KB, Pritchard E, Matthews PC, et al. Effect of Delta variant on viral burden
895 and vaccine effectiveness against new SARS-CoV-2 infections in the UK. *Nat Med* 2021.
- 896 55. Eyre DW, Taylor D, Purver M, et al. Effect of Covid-19 Vaccination on Transmission
897 of Alpha and Delta Variants. *N Engl J Med* 2022.
- 898 56. Clover BioPharmaceuticals. Clover's COVID-19 Vaccine Candidate Demonstrates
899 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of
900 Concern and Interest. 2021.
- 901 57. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273
902 SARS-CoV-2 Vaccine. *N Engl J Med* 2021;384:403-16.
- 903 58. Cromer D, Juno JA, Houry D, et al. Prospects for durable immune control of SARS-
904 CoV-2 and prevention of reinfection. *Nature Reviews Immunology* 2021.
- 905 59. Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-
906 world studies: a systematic review and meta-analysis. *Infect Dis Poverty* 2021;10:132.
- 907 60. Gupta D, Sharma P, Singh M, Kumar M, Ethayathulla AS, Kaur P. Structural and
908 functional insights into the spike protein mutations of emerging SARS-CoV-2 variants. *Cellular*
909 *and Molecular Life Sciences* 2021;78:7967-89.
- 910 61. Pan T, Hu Z, Hu F, et al. Significantly reduced abilities to cross-neutralize SARS-CoV-
911 2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains.
912 *Cellular & Molecular Immunology* 2021;18:2560-2.
- 913 62. Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-
914 19 Vaccine. *N Engl J Med* 2021;385:1172-83.

- 915 63. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1
916 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised
917 controlled trials in Brazil, South Africa, and the UK. *Lancet* 2021;397:99-111.
- 918 64. Pillet S, Arunachalam PS, Andreani G, et al. Safety, immunogenicity and protection
919 provided by unadjuvanted and adjuvanted formulations of recombinant plant-derived virus-like
920 particle vaccine candidate for COVID-19 in non-human primates. *bioRxiv*
921 2021:2021.05.15.444262.
- 922 65. Lomonosoff GP, D'Aoust MA. Plant-produced biopharmaceuticals: A case of
923 technical developments driving clinical deployment. *Science* 2016;353:1237-40.
- 924 66. AboulFotouh K, Cui Z, Williams RO, 3rd. Next-Generation COVID-19 Vaccines
925 Should Take Efficiency of Distribution into Consideration. *AAPS PharmSciTech* 2021;22:126.
- 926 67. Adejumo OA, Adejumo OA. Recalling the universal health coverage vision and equity
927 in the COVID-19 vaccine distribution plan. *Pan Afr Med J* 2021;39:197.
- 928 68. Pagliusi S, Jarrett S, Hayman B, et al. Emerging manufacturers engagements in the
929 COVID -19 vaccine research, development and supply. *Vaccine* 2020;38:5418-23.
- 930 69. Hotez PJ, Bottazzi ME. Whole Inactivated Virus and Protein-Based COVID-19
931 Vaccines. *Annu Rev Med* 2021.
- 932 70. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven
933 COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or
934 BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2
935 trial. *Lancet* 2021.
- 936 71. Gobeil P, Pillet S, Boulay I, et al. Durability and Cross-Reactivity of Immune
937 Responses Induced by an AS03 Adjuvanted Plant-Based Recombinant Virus-Like Particle
938 Vaccine for COVID-19. *medRxiv* 2021:2021.08.04.21261507.

939